BD Veritor™ Systems, BD Diagnostics

Supplier: BD Diagnostics
256055 256055 256041 256038 256088 256088 256042 256045 256040 256051 256049 256041 256061 256042
CABD256055EA 764.66 CAD
10124-818 10031-438 10031-436 10031-430 10124-734 CABD256055 CA76485-942 10031-440 10124-732 76485-942 10031-434 CABD256041 10031-432 CABD256042
BD Veritor™ Systems, BD Diagnostics
Assays Immunological Assays
The BD Veritor System uses the BD Veritor System Digital Reader and test device

The BD Veritor System for Rapid Detection of Flu A+B is a rapid chromatographic immunoassay for the direct and qualitative detection of influenza A and B viral nucleoprotein antigens from nasal and nasopharyngeal swabs of symptomatic patients. The BD Veritor System for Rapid Detection of Flu A+B (also referred to as the BD Veritor System and BD Veritor System Flu A+B) is a differentiated test, such that influenza A viral antigens can be distinguished from influenza B viral antigens from a single processed sample using a single device. The test is to be used as an aid in the diagnosis of influenza A and B viral infections. A negative test is presumptive and it is recommended that these results be confirmed by viral culture or an FDA-cleared influenza A and B molecular assay. Negative test results do not preclude influenza viral infection and should not be used as the sole basis for treatment or other patient management decisions. The test is not intended to detect influenza C antigens.

The BD Veritor System for Rapid Detection of Respiratory Syncytial Virus (RSV) is a chromatographic immunoassay with an instrumented read for the direct and qualitative detection of RSV fusion protein from a direct nasopharyngeal swab from patients suspected of having a viral respiratory infection. This test is intended for in vitro diagnostic use to aid in the diagnosis of RSV infections in infants and pediatric patients under the age of 6 years. Negative results do not preclude RSV infection and should not be used as the sole basis for treatment or for other management decisions. A negative test is presumptive. It is recommended that negative test results be confirmed by viral cell culture or an alternative method, such as a FDA-cleared molecular assay. The test is intended for professional and laboratory use. It is to be used in conjunction with the BD Veritor System Reader.

The BD Veritor System for Rapid Detection of Group A Strep is a rapid chromatographic immunoassay for the direct and qualitative detection of Group A Streptococcus antigen from throat swabs of symptomatic patients. It is intended to be used in conjunction with the BD Veritor System Reader as an aid in the diagnosis of Group A Strep. All negative test results should be confirmed by bacterial culture because negative results do not preclude Group A Strep infection and should not be used as the sole basis for treatment.

These components incorporate BD's unique Advanced Particle and Adaptive Read technologies to enhance both the sensitivity and specificity of the test, providing an objective, trustworthy result.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR